This study highlights the potential value of targeting TNFR2 to overcome the immunological barrier of the endothelium for CD8+ T cells infiltration, increase tumor responsiveness to PTX therapy and facilitate its combination with immunotherapy. Here, TNFRSF1B is linked to neoplasm.